Moreover, we found ANXA5 was highly expressed in glioma cells and contributes to tumor progression in vitro and in vivo and illustrated the potential molecular mechanisms that ANXA5 functions through the MAPK/CD44 pathway, which might provide a basis of clinical significance for ANXA5 in glioma treatment. Here, CD44 is linked to neoplasm.